For more than 2 centuries active immunotherapy has been at the forefront of efforts to prevent infectious disease [Waldmann TA (2003) Nat Med 9:269 -277]. However, the decreased ability of the immune system to mount a robust immune response to selfantigens has made it more difficult to generate therapeutic vaccines against cancer or chronic degenerative diseases. Recently, we showed that the site-specific incorporation of an immunogenic unnatural amino acid into an autologous protein offers a simple and effective approach to overcome self-tolerance. Here, we characterize the nature and durability of the polyclonal IgG antibody response and begin to establish the generality of p-nitrophenylalanine (pNO 2Phe)-induced loss of self-tolerance. Mutation of several surface residues of murine tumor necrosis factor-␣ (mTNF-␣) independently to pNO2Phe leads to a T cell-dependent polyclonal and sustainable anti-mTNF-␣ IgG autoantibody response that lasts for at least 40 weeks. The antibodies bind multiple epitopes on mTNF-␣ and protect mice from severe endotoxemia induced by lipopolysaccharide (LPS) challenge. Immunization of mice with a pNO 2Phe 43 mutant of murine retinol-binding protein (RBP4) also elicited a high titer IgG antibody response, which was cross-reactive with wild-type mRBP4. These findings suggest that this may be a relatively general approach to generate effective immunotherapeutics against cancer-associated or other weakly immunogenic antigens.
C
ritical to the process of immunological self-nonself discrimination is self-tolerance (1), in which a mammal's immune system is ''tolerized'' to self-proteins to avoid autoimmune disease, primarily due to the absence or inactivation of selfreactive B or T cells. It has been known for years, however, that the immune system can be induced to attack self-proteins. For example, cross-reactive immune responses to self-proteins can be induced by introducing foreign T helper cell epitopes into chimeric antigens (2, 3) , by extensive chemical derivatization of self-antigens (4) , and by DNA vaccines (5) . Furthermore, a number of specific genes and cellular mechanisms involved in self-tolerance have been identified which when disrupted result in breakdown of tolerance and autoimmune disease (1, 6) . Despite these advances, the design of effective immunotherapeutics has been a slow process, as exemplified by the fact that only a few vaccines for cancer treatment have reached late stage clinical development (7, 8) .
Nitroaryl groups are highly immunogenic, likely due to their ability to form strong stacking and van der Waals interactions. Indeed, the nonspecific derivatization of autologous cancer cells with dinitrophenyl groups has been exploited as a vaccine in melanoma patients (9) , and physiological 3-nitrotyrosine formation has been implicated in the pathology of a number of autoimmune diseases (10) (11) (12) . To test whether this immunogenic group could be used to break tolerance to specific selfproteins, we previously introduced a p-nitrophenylalanine (pNO 2 Phe) residue at a single site in murine TNF-␣. Genetic substitution of pNO 2 Phe for Tyr-86 of mTNF-␣ created a T cell epitope, which enhanced T cell help to elicit a strong crossreactive antibody response against this disease-related selfprotein (13) . Here, we show that immunochemical breakdown of self-tolerance leads to sustained high-titer antibody responses that efficiently protect mice against a lipopolysaccharide (LPS) challenge. Moreover, we demonstrate that this methodology is generalizable to a self-protein unrelated to immune function, namely retinol binding protein 4 (RBP4).
Results and Discussion
Mechanistic Studies of pNO2Phe-Induced Breakdown of SelfTolerance. Previously, we showed that substitution of pNO 2 Phe for Tyr-86 in mTNF-␣ led to a high titer cross reactive antibody response to wildtype (WT) protein. The mutant protein was shown to induce T cell proliferation in immunized animals, whereas WT protein did not (13) . To provide further evidence for a T cell-dependent immune response against pNO 2 Phe TNF-␣ we have carried out ELISA analysis of the mTNF-␣ autoantibodies with either anti-mouse IgM or anti-mouse IgG secondary antibody. The majority of the anti-mTNF-␣ autoantibodies in sera from Bcl-2 transgenic mice [C57BL/6-TgN(BCL2)22Wehi] immunized with pNO 2 Phe 86 mTNF-␣ are of the IgG subtype indicating T cell-mediated Ig class switching (Fig. 1A) . To determine whether the presence of pNO 2 Phe is critical throughout the immunization process, we initially injected 4 mice with pNO 2 Phe 86 mTNF-␣ in complete Freund's adjuvant (CFA) followed by 7 injections of either WT mTNF-␣ or pNO 2 Phe 86 mTNF-␣ in incomplete Freund's adjuvant (IFA). The results shown in Fig. S1 clearly demonstrate that, in contrast to pNO 2 Phe 86 mTNF-␣, WT mTNF-␣ cannot sustain significant titers of cross-reactive anti-mTNF-␣ antibodies. This result supports the notion that pNO 2 Phe-induced breakdown of selftolerance requires a T cell response mediated by the nitrophenyl Author contributions: J.G., L.D., M.-L.T., R.P., W.R., M.N., R.A.L., P.G.S., and V.S. designed research; J.G., G.S.H., L.D., F.N., B.G.W., M.-L.T., R.P., and B.A.L. performed research; J.G., G.S.H., L.D., F.N., B.G.W., M.-L.T., R.P., M.K., B.A.L., S.A., W.R., M.N., R.A.L., P.G.S., and V.S. analyzed data; and J.G., P.G.S., and V.S. wrote the paper.
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group, and is consistent with previous studies that showed that a Tyr86Phe mTNF-␣ mutant is not able to elicit a strong immune response.
One question regarding the mechanism of pNO 2 Phe-induced breakdown of self-tolerance is whether the antibody response is directed at the epitope that contains pNO 2 Phe, or whether epitope spreading occurs, resulting in a polyclonal IgG response against multiple epitopes in the target protein. To address this issue, Bcl-2 transgenic mice were immunized with pNO 2 Phe 86 mTNF-␣ to generate 50 B cell hybridomas, which were screened by ELISA to identify those clones that produced antibodies against WT mTNF-␣. We then assessed the binding of these monoclonal antibodies (mAbs) to a set of 3 mTNF-␣ fragments that were expressed in E. coli and whose molecular masses were verified by MALDI-TOF (Fig. S2 ): an N-terminal fragment (amino acid 1-60), an internal fragment (amino acid 61-100), and a C-terminal fragment (amino acid 101-156). Although this assay largely detects specificities against linear (presumably continuous) B cell epitopes, we identified 5 mAbs (3L24, 5K19, 6J22, 7O1, and 7F23) that bound the N-terminal fragment and 1 mAb (1P19) that bound the C-terminal fragment (Fig. S3) . Significantly, none of the mAbs bound the internal fragment encoding pNO 2 Phe 86 in the original immunogen. Thus, antibodies that bind more than 1 epitope are produced through pNO 2 Phe 86 mTNF-␣ immunization, and these epitopes do not necessarily include the pNO 2 Phe residue of the immunogen. The polyclonal IgGs from pNO 2 Phe 86 mTNF-␣ immunized mice cross react with native mTNF-␣ with K d values in the nanomolar range (Fig. 1B) . Together, these results further support the hypothesis that a cross-reactive neutralizing antibody response can be generated against a self-protein by simply substituting a pNO 2 Phe residue into its sequence.
Sustainability of pNO2Phe-Induced Antibody Response. To determine the durability of anti-mTNF-␣ IgG antibody titers, we immunized 3 Bcl-2 transgenic mice with the pNO 2 Phe 86 mTNF-␣. After the last boost injection, bleeds were analyzed by ELISA against pNO 2 Phe 86 mTNF-␣ at defined time points. Remarkably, antibody levels were maintained at Ͼ80% their initial levels for at least 40 weeks (Fig. 1C) , after which time the mice were killed. In contrast, in a previous anti-mTNF-␣ vaccination study based on immunization with mTNF-␣ mutant containing a hen egg-white lysozyme T cell epitope, titers declined 4 weeks after the last boost, and after 26 weeks the anti-mTNF-␣ antibody titers had dropped by 80-87% (2). Thus, our pNO 2 Phe-based vaccine strategy is effective in inducing persistent immunity and long-term protection against TNF-␣ as a disease-associated self-antigen.
Extension to Mutations at Other Surface Sites Within mTNF-␣.
To examine the generality of the pNO 2 Phe-induced breakdown of self-tolerance, 4 additional surface-exposed residues of mTNF-␣ were mutated to pNO 2 . S4B and Table 1 ), the quaternary structure of these mutant proteins was shown to be trimeric by size exclusion chromatography (Table S1 ). Furthermore, an NFB-luciferase reporter gene assay showed that pNO 2 Phe 11 mTNF-␣ has 9%, pNO 2 Phe 21 mTNF-␣ has 22%, pNO 2 Phe 42 mTNF-␣ has 22%, and pNO 2 Phe 49 mTNF-␣ has 10% of the activity of WT mTNF-␣ (Table S1 and Fig. S4C ). All mutants are therefore significantly more active than the previously characterized pNO 2 Phe 86 mTNF-␣, which has only 2% of the activity of the wild-type protein in this assay. To determine the immunogenicity of these pNO 2 Phe mTNF-␣ mutants, 14 C57BL/6 mice were randomized into 5 groups and injected with these mutants, or WT mTNF-␣ by the RIMMS (repetitive immunization at multiple sites) protocol (14) . An ELISA analysis revealed no correlation between mTNF-␣ activity in the NFB-luciferase reporter gene assay and the ability to induce an antibody response, ruling out a direct effect on the immune system. As shown in Fig. 2 , pNO 2 Phe at position 11 induced a high titer IgG response to WT mTNF-␣, equivalent to that against the pNO 2 Phe 86 mTNF-␣ immunogen. In contrast, although mutations of positions 21, 42, and 49 also yielded high titer IgG responses against the pNO 2 Phe-containing immunogen, the IgG antibodies had only moderate cross-reactivity to WT mTNF-␣. Antibodies generated against all 4 mutant TNF-␣'s were then used for passive immunization of forty C57BL/6 mice, which were randomized into 5 groups and injected with the anti-pNO 2 Phe or anti-WT mTNF-␣ IgG. Twenty-four hours after passive immunization, the animals were challenged with LPS as described in ref. 15 . All mice receiving anti-pNO 2 Phe 11 mTNF-␣ IgG survived the lethal LPS challenge (Fig. 3) . Even the other groups receiving moderately cross-reactive anti-pNO 2 Phe 21 mTNF-␣ IgG, anti-pNO 2 Phe 42 mTNF-␣ IgG, and anti-pNO 2 Phe 49 mTNF-␣ IgG had survival rates of at least 75%; whereas mice injected with anti-WT mTNF-␣ IgG showed a survival rate of only 13%. Thus, the ability to break self-tolerance using pNO 2 Phe is not dependent on a single amino acid position, since we have shown that at least 5 positions (including position 86) can induce a neutralizing cross-reactive anti-mTNF-␣ IgG response in vivo. Moreover, the site of substitution does not need to be structurally similar to pNO 2 Phe.
Expression and Characterization of Mutant mRBP4 Proteins. Given that multiple positions within mTNF-␣ lead to breakdown of self-tolerance when mutated to pNO 2 Phe, we then asked whether this methodology could be generalized to other selfproteins. Specifically, we examined the ability of pNO 2 Phe to break self-tolerance against another model self-protein found in serum, RBP4 (16, 17) . In contrast to TNF-␣ this is a highly soluble, relatively low molecular mass (20 kDa), monomeric protein. RBP4 knockout mice show no apparent phenotypic abnormalities other than visual deficiency (18) , suggesting that mice will survive a neutralizing immune response against self-RBP4. Based on the X-ray crystal structure of monomeric human RBP4 (19), we selected the following surface-exposed residues for mutation to pNO 2 Phe: Tyr 43 and Tyr 108 (Fig. S5A ). These residues are highly conserved among different mammalian RBP4s, including murine RBP4 (mRBP4). These mRBP4 mutants and WT mRBP4 were expressed in E. coli as N-terminal His 6 -tagged proteins, purified by Ni 2ϩ affinity chromatography under denaturing conditions, and refolded according to a previously described protocol (20) . The site-specific incorporation of pNO 2 Phe into mRBP4 at positions 43 and 108 was confirmed by SDS/PAGE analysis, and by MS/MS fragmentation of the tryptic fragments containing the unnatural amino acid (Figs. S5 and S6 and Table S2 ). Analytical size-exclusion chromatography indicated a monomeric structure for all mRBP4 proteins, which is in agreement with the published quaternary structure of human RBP4 (Table S3) (19) . Moreover, according to a retinol displacement assay, all pNO 2 Phe mRBP4 mutants bind retinol with K d values in the nanomolar range, which is in good agreement with WT mRBP4 (Table S3) .
Generality of pNO2Phe-Induced Breakdown of Self-Tolerance. To determine the immunogenicity of the pNO 2 Phe mRBP4 mutants, 9 Bcl-2 transgenic mice were randomized into 3 groups and injected with pNO 2 Phe 43 mRBP4, pNO 2 Phe 108 mRBP4 and WT mRBP4 by the RIMMS protocol (14) . According to ELISA analysis, mice immunized with either W T mRBP4 or pNO 2 Phe 108 mRBP4 had insignificant serum IgG titers against WT mRBP4 (Fig. 4A) . In contrast, mice immunized with pNO 2 Phe 43 mRBP4 were found to display markedly high serum IgG titers (up to 1:100,000), binding both the pNO 2 (Fig. S7) . Furthermore, in accordance with previous observations with pNO 2 Phe 86 mTNF-␣, CD4
ϩ T cells specific for pNO 2 Phe 43 mRBP4 were induced upon immunization with pNO 2 Phe 43 mRBP4 protein, indicating a mature T cell-dependent immune response (Fig.  4B) . Together, these results further support the hypothesis that the introduction of pNO 2 Phe into a protein sequence can create a strong T cell epitope, which initiates a sustained cross-reactive IgG antibody response. Not all sites lead to a strong crossreactive immune response, which is not surprising since it is unlikely that all sites correspond to potential T cell epitopes.
Conclusion
We have shown that the genetic introduction of pNO 2 Phe leads to sustained IgG antibody responses against the self-proteins mTNF-␣ and mRBP4. In terms of mechanism, incorporation of the p-nitrophenyl group at a single position results in T cells that can only be stimulated by the pNO 2 Phe mutant but not the WT protein. This pNO 2 Phe-induced T cell-dependent response ultimately leads to activation of autoreactive B cells and the production of polyclonal antibodies that are highly cross-reactive to the native self-protein. These results are comparable to recent studies showing that posttranslationally modified proteins can enhance T cell responsiveness (21) (22) (23) . For example, citrullination and glycosylation are posttranslational modifications reported to be involved in T cell-dependent autoimmune diseases (21) (22) (23) (24) (25) . Similarly, dinitrofluorobenzene modification of skin antigens has been used for decades as a model of the T cell response in contact hypersensitivity (26) . Site-specific incorporation of pNO 2 Phe into self-proteins therefore establishes a simple model system to biochemically mimic posttranslationally or chemically mediated loss of self-tolerance. This methodology should therefore also help to understand how the immune system responds to chemically modified antigens during autoimmunity. Furthermore, pNO 2 Phe-induced breakdown of self-tolerance should not only afford a robust method for raising neutralizing antibodies against pathogenic self-proteins associated with cancer or degenerative diseases, it may also be applicable to weakly immunogenic foreign antigens of infectious agents.
Materials and Methods
Bacterial Strains and Reagents. E. coli XL1-Blue and XL10-Gold were used as hosts for cloning, and E. coli BL21(DE3) was used as an expression strain. Restriction enzymes, T4 DNA ligase, dNTPs, and factor Xa protease were obtained from NEB (Beverly, MA). Primers were purchased from Integrated DNA Technologies (Coralville, IA). Plasmid DNA preparation was carried out with PureLink Quick Plasmid Miniprep Kit (Invitrogen), and DNA purification after restriction digestion was performed using PureLink PCR Micro Kit (Invitrogen).
Production of pNO2Phe-Containing mTNF-␣ and WT mTNF-␣. WT mTNF-␣ and pNO2Phe mTNF-␣ mutants were produced as described in ref. 13 . Briefly, site-specific incorporation of pNO2Phe into the murine TNF-␣ gene was carried out by introducing TAG amber codons using standard PCR mutagenesis procedures. To express pNO2Phe mTNF-␣ mutants, E. coli BL21(DE3) cells were cotransformed with mutNO2PheRS, mutRNACUA and the mutated mTNF-␣ gene. The transformed cells were then grown in the presence of 1 mM pNO2Phe (Alfa Aesar) in minimal medium containing 1% glycerol and 0.3 mM leucine (GMML medium) at 37°C and protein expression was initiated by the addition of 1 mM IPTG. WT mTNF-␣ was expressed in 2ϫ YT medium in the absence of pNO2Phe. Protein purification was carried out by immobilized metal affinity chromatography (IMAC) and size-exclusion chromatography (SEC) under either native or denaturing conditions. All proteins were characterized by MALDI-TOF or ESI mass spectrometry. Successful incorporation of pNO2Phe into mutant proteins was also verified by tryptic in-gel digestion and subsequent MS/MS fragmentation of the respective tryptic fragment containing this unnatural amino acid. Protein quaternary structures were analyzed by analytical SEC on a Superdex 75 10/300 GL gel filtration column, which was calibrated by a molecular weight gel-filtration standard from Bio-Rad. The activity of pNO2Phe mTNF-␣ mutants was determined by an NFB-luciferase reporter gene assay using HEK293 cells stably expressing NFB-luciferase as described in ref. 13 .
Construction of mRBP4 Expression
Vector, pSpeedET-mRBP4. The cDNA encoding murine RBP4 (amino acid 19 -201) (Genomics Institute of the Novartis Research Foundation) was amplified with PCR using 2 primers designed specifically for the Polymerase Incomplete Primer Extension (PIPE) cloning method (27) : 5Ј-CTGTACTTCCAGGGCGAGCGCGACTGCAGGG (5Ј insert forward primer) and 5Ј-AATTAAGTCGCGTTACAAACTGTTTCTGGAGGGCC (3Ј insert reverse primer). The pSpeedET vector was amplified using a 5Ј vector reverse primer 5Ј-GCCCTGGAAGTACAGGTTTTCGTGATGATGATGATGATG and a 3Ј vector forward primer 5Ј-TAACGCGACTTAATTAACTCGTTTA-AACGGTCTCCAGC. The underlined and italicized bases highlight the 2 distinct complementary regions between primers where annealing occurs. The pSpeedET vector appends an N-terminal His6-tag sequence (MGSDKIHHH-HHH), followed by a TEV protease site (ENLYFQG) immediately before the 19 th codon for mRBP4. The unpurified mRBP4 (amino acid 19 -201) insert PCR product was mixed 1:1 (vol/vol) with the unpurified pSpeedET vector PCR product. After mixing, E. coli XL10-Gold cells were transformed with 2 L of the reaction mixture. Site-specific incorporation of pNO 2Phe into mRBP4 (amino acid 19 -201) was performed by mutating the codons for Tyr 43 or Tyr 108 to a TAG amber codon. The sequences of all pSpeedET-mRBP4 constructs were confirmed by DNA sequence analysis.
Protein Expression and Purification of pNO2Phe mRBP4 and WT mRBP4. To express the pNO2Phe mRBP4 mutants, E. coli BL21(DE3) cells were cotransformed with mutNO2PheRS, mutRNACUA, and the respective mutant mRBP4 gene. The transformed strains were grown at 37°C in the presence of 1 mM pNO2Phe in GMML medium, induced with 0.2% (wt/vol) arabinose when the OD600 reached 0.5, and harvested after 12-16 h. In contrast to the pNO2Phe mRBP4 mutants, WT mRBP4 was expressed in 2x YT medium in the absence of pNO2Phe for 3 h. The cell pellets were suspended in 8 M urea containing 100 mM NaH2PO4, 10 mM Tris (pH 8.0) and lysed by sonication on ice for 3 min. Cell debris was removed by centrifugation at 40,000 ϫ g for 25 min. Five milliliters of 50% Ni-NTA slurry (Novagen) was added to the supernatant and mixed gently by shaking for 60 min. The Ni-NTA beads were washed with 8 M urea, 100 mM NaH2PO4, and 10 mM Tris (pH 6.3). Elution was carried out with 8 M urea containing 100 mM NaH2PO4, and 10 mM Tris (pH 4.5). The protein was concentrated with a 10K molecular mass cut-off Amicon Ultra-15 centrifugal filter device (Millipore). The mRBP4 protein was precipitated by dialysis against PBS (pH 7.4), and redissolved in 8 M urea containing 20 mM Tris and 20 mM DTT (pH 8.0). In vitro folding of mRBP4 protein was performed according to Greene et al. (20) . Briefly, native protein was generated by adding the denatured material in 8 M urea dropwise to folding buffer containing 20 mM Tris, 10 mM ␤-mercaptoethanol, 1 mM 2-hydroxyethyldisulfide, and 1% glycerol (pH 8.5) at a rate of Ϸ30 drops/min. Folding was allowed to proceed for 16 h at 4°C, and the protein solution was then concentrated using a 10K molecular mass cut-off Amicon Ultra-15 centrifugal filter device (Millipore). The protein was further purified by SEC on a Superdex 75 10/300 GL column (GE Healthcare) equilibrated with PBS (pH 7.4) at a flow rate of 0.3 mL/min.
Mouse Model of Severe Systemic Inflammation. All experiments were carried out in accordance with the National Institutes of Health Animal Protection Guidelines and were approved by The Scripps Research Institute Animal Care and Use Committee. Animal experiments were performed in a room with alternating 12 h light-dark cycles under stable conditions of temperature (20 -22°C) and relative humidity (40 -60%) (15) . Twenty-four hours before LPS challenge, 9-week old male C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) were passively immunized by injection into the left half of the peritoneal cavity with 4 mg/kg of IgG purified from serum of mice immunized with pNO2Phe 11 mTNF-␣, pNO2Phe 21 mTNF-␣, pNO2Phe 42 mTNF-␣, or pNO2Phe 49 mTNF-␣. IgG derived from nonimmunized wild-type mice was used as a negative control. Mice were then injected into the right half of the peritoneal cavity under 2% isoflurane with 7.5 mg/kg lipopolysaccharide (LPS) (E. coli O111:B4 Calbiochem/EMD Biosciences). For statistical analysis, Kaplan-Meier curves were plotted and survival differences were analyzed using a log rank test with Bonferroni correction.
